anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Over the next 30 years, more than 10 million persons living with dementia in the US will receive care at home from an unpaid and untrained family caregiver. At home care is preferred by caregivers (CG) and persons with dementia (PWD) alike, but increases caregiver risk of insomnia and related negative health outcomes, including depression, anxiety, cognitive disturbances and poor quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is an effective and established evidence based treatment for adults of all ages. Although relatively understudied in dementia caregivers, the research suggests CBT-I is also efficacious in caregivers. Our team developed a brief (4 session) CBT-I protocol adapted for dementia caregivers and has shown in person and remote (i.e. telehealth) delivery of this protocol significantly reduces insomnia and improves mood (moderate to large effects). Given demands on caregiver time and limited availability of trained CBT-I providers, we developed a web-based version of this treatment (NiteCAPP) to increase accessibility of this efficacious treatment for rural dementia CGs. NiteCAPP will allow for flexible at home scheduling, and the skills needed to monitor caregiver treatment progress can be quickly and efficiently taught to healthcare providers. The Cognitive Activation Theory of Stress provides a framework for our basic premise that CGs experience insomnia, arousal and inflammation that prompt sympathetic activation and hypothalamic-pituitary-adrenal (HPA) disruption that have negative effects on health. The proposed trial tests the novel hypothesis that NiteCAPP will improve CG health, mood, burden and cognition by targeting their shared mechanisms - sleep, arousal and inflammation - thereby, returning sympathetic and HPA functioning to normal. Another novel aspect of the proposed trial is inclusion of behavioral strategies to target the PWD sleep. Objectives: The goal of this project evaluate the efficacy of NiteCAPP in improving insomnia in a rural dementia caregiver sample (n of 100 caregiver and PWD dyads). We will measure both the short term (post-treatment) and long term (6 and 12 months) effects of the intervention on CG sleep, arousal, inflammation, health, mood, burden and cognitive function, and PWD sleep.
Children and adolescents in the experimental group attend 6 modules of video-based transdiagnostic rational emotive behavioral therapy (REBT). Each of the six modules aimes a different component: Psychoeducation, Relaxation, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/ behavior activation and problem solving, Maintenance of gaining.
PURPOSE:To provide the subject promoter containing, as active ingredient, microbial cells belonging to Bifidobacterium thermophilum and/or Lactobacillus salivarius. CONSTITUTION:The objective promoter containing, as active ingredient, microbial cells obtained by culture of Bifidobacterium thermophilum and/or Lactobacillus salivarius of esp. avian origin. This promoter is either administered after addition of an additive into a dry or liquid pharmaceutical, or administered after direct addition to a feed, being applicable to poultry such as chickens, quails, guinea fowls, ducks, turkeys, and pigeons. The microorganisms are anaerobically cultured at 30-42 deg.C, and after culture, cooled and separated. The microbial cells thus recovered is dispersed in a phosphate buffer solution or water containing an amino acid followed by lyophilization. In using this promoter, the surface of the microbial cell powder is pref. coated with an enteric base.
A welding helmet with a sensor-operated light and photochromic visor lens including a welding helmet body configured, sized, and shaped to cover and substantially conform to a welder's forehead. A frustoconical protrusion, integrated into a front side of the welding helmet body, houses a battery-operated LED light bulb. At least one photosensor is disposed proximal the protrusion. Upon the detection of a welding arc by the at least one photosensor, an auto-darkening filtered visor lens darkens and the LED light bulb in activated. A battery compartment, an on-off switch, and a microchip are disposed on a rear side of the welding helmet body. A padded length-adjustable strap is pivotally disposed across the rear side of the welding helmet body.
Olfactory and gustatory dysfunction have been reported in mild and major neurocognitive disorders (NCDs), with variable results. While olfactory dysfunction has been consistently explored, reports on gustatory alterations are limited. We systematically reviewed case-control studies evaluating gustatory function in NCDs with various etiologies and different neuropathology. Eighteen studies were included in the systematic review, and eight were included in the meta-analysis. Most studies were on Alzheimer's disease (AD) and Parkinson's disease (PD). Pooled analyses showed worse global taste threshold and identification (sour in particular) scores in AD than controls and worse global, sweet, and sour scores in AD compared to mild cognitive impairment (MCI). PD with MCI showed worse global, sweet, salty, and sour scores than controls and cognitively unimpaired PD. Taste dysfunction was differentially associated with the severity of cognitive deficits. Gustatory dysfunction may represent a potential cross-disease chemosensory biomarker of NCD. Whether gustatory alterations may be a pre-clinical biomarker of NCD requires further studies.
PURPOSE:To obtain a tape for sleepiness prevention by compounding a tacky adhesive coating layer mainly containing a styrene-isoprene-styrene block copolymer with 1-menthol. CONSTITUTION:A tacky adhesive base material is an amount of 100 pts.wt. which is composed of 100 pts.wt. of styrene-isoprene-styrene block copolymer, 80-180 pts.wt. of an alicyclic hydrocarbon resin and 10-200 pts.wt. of isopropyl myristate is compounded with 9-30 pts.wt. of 1-menthol. This mixture is applied on a supporting member to obtain a tacky adhesive layer. The tacky adhesive layer is produced into a sheet-shaped, a tape-shaped, a circular, an oval or a rhombic material, etc., by a solvent coating method or a hot-melt coating method. This tape can be produced without deteriorating tacky adhesivity despite that 1-menthol is compounded. The tape rapidly exhibits sleepiness- preventing effect after plastering and holds it for a long time.
A continuous adductor canal block (cACB) for pain control in total knee arthroplasty (TKA) is always performed by an anesthesiologist. A surgeon-performed cACB during surgery is somewhat questionable in terms of feasibility, reproducibility, and efficacy. This study was divided into two phases. In Phase 1 study, an experimental dissection of 16 cadaveric knees to expose the saphenous nerve and related muscles around the adductor canal was conducted. The extent of dye after injection via a catheter inserted into the adductor canal at the time of TKA was evaluated. In Phase II, a randomized controlled trial study comparing clinical outcomes between surgeon-performed (Group 1) and anesthesiologist-performed cACB (Group 2) during TKA in 63 patients was evaluated. The visual analogue scale (VAS) at rest and during movement at several time points and functional outcomes during hospitalization were compared. The Phase I study demonstrated surgeon-performed cACB during surgery feasible and reproducible with consistent dye extension into the adductor canal after injection via a catheter. In the Phase II study, 29 patients of Group 1 and 30 patients of Group 2 completed the evaluation with no differences in baseline parameters. The VAS during movement at 24 and 36 hours, quadriceps strength, time up and go test, and knee motion at different time points, and total morphine consumption showed no differences between both groups. There were no procedure-related complications. The surgeon-performed cACB during surgery was feasible and reproducible with similar VAS scores and functional outcomes during hospitalization to anesthesiologist cACB. Level of evidence is Level I, prospective randomized trial.
Pembrolizumab will be administered via IV Infusion followed by subcutaneous injections of PDS0101 five times throughout the course of the study. Pembrolizumab monotherapy will be administered every cycle there is not a combination treatment until disease progression or up to Cycle 35.
From July 2003 to May 2007, over 50 patients with liver metastases participated in two studies at Princess Margaret Hospital (PMH) designed to determine the safety of treating liver metastases with SBRT. These studies have shown that SBRT can be delivered safely to the majority of patients with liver metastases. The treated tumour was controlled (shrank or remained the same size) in 74% of patients at one year following treatment. The median survival of patients was 16 months (i.e.half of patients survived longer and half shorter than 16 months). This survival rate is better than that expected in patients whose tumours grew bigger even though they were treated with chemotherapy. Supportive care only (no treatment other than care to make you feel better) in these patients is associated with a median survival rate of 6-12 months. We expect that the benefits of SBRT in this study will be similar to those observed in our initial studies.
Four hours after breakfast a small amount of liquid to drink will be given to a participant that will contain either the Appethyl™ or placebo. Participants will be given a lunch of about 750 calories and 40% fat prepared by the Metabolic Kitchen and be asked to eat all of it. Participants will have food choice testing performed 4 hours after starting their lunch meal. This will be done in two ways. Participants will be given a list of two foods that are made of carbohydrate like bread and pretzels and be asked which is most preferred. Participants will also be given a list of foods that differ in the amounts of fat, carbohydrate and protein that they contain and will be asked to mark the ones that appeal to them.

Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
American Indian/Alaskan Natives (AI/AN) have the worst cancer survival rates of any U.S. racial group and are 1.6 times more likely to be obese than the general population. Inflammation is a reversible mechanism through which obesity increases the risk of cancer incidence and progression. Prehabilitation (prehab) is a strategy utilizing lifestyle modifications in physical activity, nutrition, smoking cessation, and/or psychological support to optimize patients' functional capacity and improve postoperative outcomes. The proposed project is to (1) implement the prehab translational clinical trial for AI patients with obesity-related solid tumor cancer preparing for surgery and (2) measure inflammatory biomarkers pre and post-intervention to assess responsiveness. The intervention will be piloted in a sample of 30 patients with obesity-related solid tumor cancer who are enrolled tribal members, age 18-80 years, undergoing surgical resection of the tumor with at least 3 weeks until operation. Patients will eat walnuts, and exercise by walking 30 minutes daily and attending fitness sessions twice weekly during the 3 week study period. Patients will complete pre and post surveys, 6 minute walk test, 30 second sit-to-stand test, biosample collection and anthropometric measurements. These assessments will help us understand if the walnuts and exercise can mitigate inflammation in the tumor. Prior published programs have featured similar sized groups for feasibility testing. Patient reported acceptability, lifestyle behavior change, and biosample collection rates will be evaluated to assess feasibility and gain effect size estimates for a future R01 trial.
The patient is his own comparator. During the intervention, the eyes movements measurements will be performed using the standard of care and the medical device S360.
Two multicenter, double-blind, randomized, placebo-controlled studies were conducted to evaluate the effectiveness of YAZ in treating the symptoms of PMDD. Women aged 18-42 who met DSM-IV criteria for PMDD, confirmed by prospective daily ratings of their symptoms, were enrolled. Both studies measured the treatment effect of YAZ using the Daily Record of Severity of Problems scale, a patient-rated instrument that assesses the symptoms that constitute the DSM-IV diagnostic criteria. The primary study was a parallel group design that included 384 evaluable reproductive-aged women with PMDD who were randomly assigned to receive YAZ or placebo treatment for 3 menstrual cycles. The supportive study, a crossover design, was terminated prematurely prior to achieving recruitment goals due to enrollment difficulties. A total of 64 women of reproductive age with PMDD were treated initially with YAZ or placebo for up to 3 cycles followed by a washout cycle and then crossed over to the alternate medication for 3 cycles. 

Efficacy was assessed in both studies by the change from baseline during treatment using a scoring system based on the first 21 items of the Daily Record of Severity of Problems. Each of the 21 items was rated on a scale from 1 (not at all) to 6 (extreme); thus a maximum score of 126 was possible. In both trials, women who received YAZ had statistically significantly greater improvement in their Daily Record of Severity of Problems scores. In the primary study, the average decrease (improvement) from baseline was 37.5 points in women taking YAZ, compared to 30.0 points in women taking placebo.
Participants in a 3,5 week vocational rehabilitation program (containing cognitive therapy and physical exercise) are instructed to use a computer-based working memory training program (named CogMed) each weekday (5 days a week) for 5 weeks. Each training session consists of 8 different tasks and lasts 40-50 minutes.
INTRODUCTION AND OBJECTIVES: Artificial urinary sphincter (AUS) is a treatment option for women with stress urinary incontinence (SUI) after failure of previous surgery or as a primary procedure in severe intrinsic sphincter deficiency (ISD). The aim of the study was to assess the long-term efficacy and risk factors for surgical revision and definitive explantation of AUS laparoscopic implantation in female patients.
METHODS: A retrospective review of all women submitted to AUS implantation between April 2005 and March 2023 was conducted. The AUS was implanted via transperitoneal laparoscopic approach, by two experienced surgeons. The primary endpoint was postoperative continence. Continence was defined as no leakage and no pad usage or leakage and/or pad usage with no impact on social life and failure as leakage and/or pad usage impacting social life. As secondary outcomes, clinical predictive factors for AUS revision and definitive explantation were evaluated.
RESULTS: In the last 18 years, females with a mean age of 68±12 years-old were submitted to laparoscopic implantation of AUS. Early overall complication rate was 16%, but only one case was Clavien-Dindo ≥3. After a median follow-up of 67 months, 22.2% of the patients needed a device revision, the majority due to mechanical device dysfunction. AUS definitive explantation was performed in 16%, mainly due to urethral/vaginal erosion (9.9%) and infection (6.2%). Patients with age ≥70 years and follow-up ≥10 years significantly predisposed for device revision. At the time of the last follow-up, 72% of the patients were keeping the urinary continency.
CONCLUSIONS: Laparoscopic AUS implantation in females is an effective treatment for SUI due to ISD. Meanwhile, adequate patient selection, multidisciplinary evaluation and careful expectation management are essential to achieving good results, concerning their significant complication rate.
PROBLEM TO BE SOLVED: To provide a lipophilically surface treated powder having excellent smooth feeling and detergency.SOLUTION: The lipophilically surface treated powder is prepared by surface treating an inorganic powder of fine particles of titanium oxide or fine particles of zinc oxide having a primary particle diameter of 5 nm to 150 nm with N-acylamino acid or its salt as a surface treating agent. The surface treating agent of the amount of 0.5 to 30.0 pts.wt. is used for 100 pts.wt. of the inorganic powder. N-acylamino acid is acylamino acid with amino acid selected from 12-20C saturated fatty acid, aspartic acid and glutamic acid. The salt is a salt of a metal selected from Fe, Zn, Ca, Mg, Al, Zr and Ti. The process of surface treatment is performed in the state of under water or the water containing state at a surface treatment temperature of at least 60°C and less than the boiling point of water. A cosmetic material having smooth feeling, detergency, cosmetic effect and cosmetic retainability can be obtained by incorporating the powder.
TMC114-C211

TMC114-C211 is a randomized, controlled, open-label Phase 3 trial comparing darunavir/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day (given as a twice daily or as a once daily regimen) in antiretroviral treatment-naïve HIV-1-infected adult subjects. Both arms used a fixed background regimen consisting of tenofovir disoproxil fumarate 300 mg once daily (TDF) and emtricitabine 200 mg once daily (FTC).

HIV-1-infected subjects who were eligible for this trial had plasma HIV-1 RNA greater than or equal to 5,000 copies/mL. Randomization was stratified by screening plasma viral load (HIV-1 RNA less than 100,000 copies/mL or greater than or equal to 100,000 copies/mL) and screening CD4+ cell count (less than 200 cells/mm3 or greater than or equal to 200 cells/mm3). Virologic response was defined as a confirmed plasma HIV-1 RNA viral load less than 50 copies/mL. Analyses included 689 subjects in trial TMC114-C211 who had completed 192 weeks of treatment or discontinued earlier.

Demographics and baseline characteristics were balanced between the darunavir/ritonavir arm and the lopinavir/ritonavir arm (see Table 19). Table 19 compares the demographic and baseline characteristics between subjects in the darunavir/ritonavir 800/100 mg once daily arm and subjects in the lopinavir/ritonavir 800/200 mg per day arm in trial TMC114-C211.

Week 192 outcomes for subjects on darunavir/ritonavir 800/100 mg once daily from trial TMC114-C211 are shown in Table 20.

In trial TMC114-C211 at 192 weeks of treatment, the median increase from baseline in CD4+ cell counts was 258 cells/mm3 in the darunavir/ritonavir 800/100 mg once daily arm and 263 cells/mm3 in the lopinavir/ritonavir 800/200 mg per day arm. Of the darunavir/ritonavir subjects with a confirmed virologic response of < 50 copies/mL at Week 48, 81% remained undetectable at Week 192 versus 68% with lopinavir/ritonavir. In the 192 week analysis, statistical superiority of the darunavir/ritonavir regimen over the lopinavir/ritonavir regimen was demonstrated for both ITT and OP populations.
Particles of a primary emulsion of an oil in a hydrophilic liquid containing a thickening agent are encapsulated by a process wherein the said primary emulsion is dispersed to form a secondary emulsion in an aqueous dispersion of at least two concervating colloids at least one of which is a gelable hydrophilic colloid and at least one is an isoelectric colloid (and optionally containing a thickening agent) at a temperature above the gel point of the gelable colloid and causing coacervation of the colloids on to the primary emulsion particles, e.g. by the addition of water or alteration of pH of the coacervating medium. Suitable thickening agents are materials which are substantially insoluble in the oil phase of the primary emulsion and are capable of imparting lipophilic character to the surface of the external phase of the primary emulsion; e.g. acacia, tragacanth, methyl- and carboxymethyl-cellulose, magnesium aluminium silicate, polyglycols, glycerine and syrups.  As suitable colloids there are mentioned gelatine, agar-agar, albumen, alginates, casein, pectins, acacia, starch, fibrinogen, starch-, cellulose- and amylose-acetate phthalate.  The primary emulsion may also contain a conventional emulsifying agent and either or both phases thereof may contain dissolved or suspended material which confers on the products of the invention uses as, for example, sustained release fertilizers, plant growth hormone preparations, bactericides, pesticides, ingredients for pre-mixed foods, vitamin preparations suitable for addition to dry cereal preparations, ingredients of cosmetic preparations, pharmaceutical preparations for oral, topical or injectable use (particularly of the sustained or delayed release type).  Specific examples relate to capsules comprising urea, alizarin cyanide green, methyl neopolamine bromide and hexachlorophene.  Details of the process used are given.  Specification 751,600 is referred to.
Patients receive concurrent chemoradiotherapy. The CTV includes the gross tumor, cervix, uterus, parametrium, upper part of the vagina, pelvic lymph nodes regions and para-aortic lymph nodes region. The upper border of CTV is at the level of renal vessels. A dose of 45-50.4Gy is delivered to CTV with IMRT.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and life-threatening lung disease with high mortality rates. The limited availability of effective drugs for IPF treatment, coupled with concerns regarding adverse effects and restricted responsiveness, underscores the need for alternative approaches. Kefir peptides (KPs) have demonstrated antioxidative, anti-inflammatory, and antifibrotic properties, along with the capability to modulate gut microbiota. This study aims to investigate the impact of KPs on bleomycin-induced pulmonary fibrosis.
METHODS: Mice were treated with KPs for four days, followed by intratracheal injection of bleomycin for 21 days. Comprehensive assessments included pulmonary functional tests, micro-computed tomography (µ-CT), in vivo image analysis using MMPsense750, evaluation of inflammation- and fibrosis-related gene expression in lung tissue, and histopathological examinations. Furthermore, a detailed investigation of the gut microbiota community was performed using full-length 16 S rRNA sequencing in control mice, bleomycin-induced fibrotic mice, and KPs-pretreated fibrotic mice.
RESULTS: In KPs-pretreated bleomycin-induced lung fibrotic mice, notable outcomes included the absence of significant bodyweight loss, enhanced pulmonary functions, restored lung tissue architecture, and diminished thickening of inter-alveolar septa, as elucidated by morphological and histopathological analyses. Concurrently, a reduction in the expression levels of oxidative biomarkers, inflammatory factors, and fibrotic indicators was observed. Moreover, 16 S rRNA sequencing demonstrated that KPs pretreatment induced alterations in the relative abundances of gut microbiota, notably affecting Barnesiella_intestinihominis, Kineothrix_alysoides, and Clostridium_viride.
CONCLUSIONS: Kefir peptides exerted preventive effects, protecting mice against bleomycin-induced lung oxidative stress, inflammation, and fibrosis. These effects are likely linked to modifications in the gut microbiota community. The findings highlight the therapeutic potential of KPs in mitigating pulmonary fibrosis and advocate for additional exploration in clinical settings.